1. In Vivo
  2. >>Global Vision

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

(Shutterstock)
Key Takeaways
  • S2 Xpeed provides €50,000 worth of acceleration services in exchange for 1-5% equity, helping start-ups transition from prototype to manufacturing.

Barcelona-based venture-backed tech accelerator S2 Xpeed symbolizes the rapid pace at which medtech companies are advancing in Europe.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

Podcast: Charles River CSO Calls For Collaboration On Non-Animal Models

 
• By Anabel Costa-Ferreira

Charles River’s CSO Julie Frearson outlines the FDA’s planned transition away from animal testing, changing attitudes to artificial intelligence, and the move to New Alternative Methods.

Trump II, Year One: Updated Version Seems Buggy For Pharma

 
• By Nielsen Hobbs

Issues that had been concerns in Trump’s first term are realities now, but industry has also seen some successes. Trump’s personalistic style of governance means that larger firms may be at an advantage because of their greater flexibility to cut deals on individual products.

Patient-Centric Strategy Drives Memo Therapeutics Forward

 
• By Anabel Costa-Ferreira

Memo Therapeutics is sharpening its focus on its lead antibody Potravitug, for BK polyomavirus (BKPyV) in kidney transplant patients as it prepares for Phase III trials and doubles down on patient engagement.

China’s Policies Prompt Reflection Among Global Medtechs As Local Players Adapt

 
• By Ashley Yeo

Chinese medtechs are expanding rapidly worldwide, but gaining market access within China itself – poised to become the world’s largest medtech market – is proving to be a very different challenge.

More from Growth

podcast

Podcast: EY’s Arda Ural On IPOs, Financial Markets And Tariffs

 
• By David Wild

EY's Arda Ural joins In Vivo to discuss the long-awaited recovery in biotech IPOs, the evolving capital markets landscape and how tariffs and TrumpRx are reshaping biopharma supply chains.

Celltrion USA’s New CMO Champions Regulatory Reform And Access

 
• By David Wild

Juby Jacob-Nara outlines her vision for expanding biosimilar uptake and leveraging policy changes to improve patient access.

Patient-Centric Strategy Drives Memo Therapeutics Forward

 
• By Anabel Costa-Ferreira

Memo Therapeutics is sharpening its focus on its lead antibody Potravitug, for BK polyomavirus (BKPyV) in kidney transplant patients as it prepares for Phase III trials and doubles down on patient engagement.